Advertisement

Journal of Neuro-Oncology

, Volume 85, Issue 2, pp 223–227 | Cite as

Capecitabine Therapy of Central Nervous System Metastases from Breast Cancer

  • Meltem Ekenel
  • Adilia M. Hormigo
  • Scott Peak
  • Lisa M. DeAngelis
  • Lauren E. Abrey
Clinical-patient Studies

Abstract

Central nervous system (CNS) metastases from breast cancer carry a poor prognosis. Systemic chemotherapy is often ineffective due to the impermeability of the blood-brain barrier (BBB) and inherent chemoresistance of CNS metastases. There are limited data supporting the use of capecitabine in this setting. Medical records of seven patients with brain metastases from breast cancer who received capecitabine treatment at Memorial Sloan-Kettering Cancer Center from 1994–2006 were reviewed. Treatment outcomes were analyzed retrospectively in those patients. Median time from breast cancer diagnosis to the development of CNS metastasis was 48 (18–165) months. Four patients had brain metastases alone, two patients had both leptomeningeal and brain metastases and one patient had leptomeningeal metastasis alone. Five out of seven patients had failed other treatment modalities before capecitabine. Three patients showed complete response (CR) and three patients had stable disease (SD) after capecitabine. The patient with leptomeningeal disease improved clinically, but refused repeat cerebrospinal fluid (CSF) studies. Median overall and progression-free survival from initiation of capecitabine was 13 and 8 months, respectively, for all patients. Capecitabine may achieve a CR and provide long-term control in patients with both leptomeningeal and parenchymal CNS metastases from breast cancer.

Keywords

Breast cancer Capecitabine Central nervous system metastases 

References

  1. 1.
    Tsukada Y, Fouad A, Pickren JW et al (1983) Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 52:2349–2354Google Scholar
  2. 2.
    Weil RJ, Palmieri DC, Bronder JL et al (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913–920PubMedGoogle Scholar
  3. 3.
    Melisko ME, Kunwar S, Prados M et al (2005) Brain metastases of breast cancer. Expert Rev Anticancer Ther 5:253–268PubMedCrossRefGoogle Scholar
  4. 4.
    Fenner MH, Possinger K (2002) Chemotherapy for breast cancer brain metastases. Onkologie 25:474–479PubMedCrossRefGoogle Scholar
  5. 5.
    Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3609–3617Google Scholar
  6. 6.
    Hikino H, Yamada T, Johbara K et al (2006) Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast 15:97–99PubMedCrossRefGoogle Scholar
  7. 7.
    Rogers LR, Remer SE, Tejwani S (2004) Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. NeuroOncol 6:63–64Google Scholar
  8. 8.
    Wang MLH, Yung WKA, Royce ME et al (2001) Capecitabine for 5-fluorouracil resistant brain metastases from breast cancer. Am J Clin Oncol 24:421–424PubMedCrossRefGoogle Scholar
  9. 9.
    Giglio P, Tremont-Lukats IW, Groves MD (2003) Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 65:167–172PubMedCrossRefGoogle Scholar
  10. 10.
    Siegelmann-Danieli N, Stein M, Bar-Ziv J (2003) Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J 5:833–834PubMedGoogle Scholar
  11. 11.
    Fabi A, Vidiri A, Ferretti G et al (2006) Dramatic regression of multiple brain metastases from breast cancer with capecitabine: another arrow at the bow? Cancer Invest 24:466–468PubMedCrossRefGoogle Scholar
  12. 12.
    Tham YL, Hinckley L, Teh BS et al (2006) Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer 7:164–166PubMedCrossRefGoogle Scholar
  13. 13.
    Church DN, Bahl A, Jones A et al (2006) Her-2 positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab—a case report. J Neurooncol 79:289–292PubMedCrossRefGoogle Scholar
  14. 14.
    Rivera E, Meyers C, Groves M et al (2006) Phase I study of capecitabine in combination with temozolomide in treatment of patients with brain metastases from breast carcinoma. Cancer 107:1348–1354PubMedCrossRefGoogle Scholar
  15. 15.
    Mata JF, Garcia-Manteiga JM, Lostao MP et al (2001) Role of human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5 (Prime)-Deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 59:1542–1548PubMedGoogle Scholar
  16. 16.
    Roche Xeloda (capecitabine) data sheetGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Meltem Ekenel
    • 1
  • Adilia M. Hormigo
    • 1
  • Scott Peak
    • 1
  • Lisa M. DeAngelis
    • 1
  • Lauren E. Abrey
    • 1
  1. 1.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations